Jennifer Leib, Senior Vice President at Cavarocchi Ruscio Dennis Associates, participated in a panel discussion called “Diagnostic Test Reimbursement: Issues & Outlook” at this year’s JP Morgan Healthcare Conference. Featuring presentations from approximately 300 companies to more than 4000 investors, this conference is widely considered to be the most strategic and informative investment conference in the healthcare sector. This is Jennifer’s second time presenting. She previously discussed the regulation of medical devices and diagnostics at the 2011 Conference. Jennifer’s co-panelists included Andrew Fish, Executive Director of AdvaMedDx, and Matthew Zubiller, Vice President for McKesson’s Decision Management business.
Jennifer provided an overview of recent changes to federal policy on the reimbursement of molecular and genetic tests and gave an outlook for 2013 on the evolving regulatory and reimbursement landscape for laboratory tests. She discussed the recently implemented coverage and payment polices for the new molecular pathology CPT codes, the unique challenges of reimbursement as the field transitions to whole genome sequencing, and the potential implications that the broader fiscal and budget debates may have on reimbursement of diagnostics.
An audio recording of the panel discussion requires registration but is free of charge and can be found here: https://events.jpmorgan.com/